Fucoidan from Sargassum thunbergii obtained via step gradient ethanol precipitation indicate potential anti-obesity and anti-hepatic steatosis in vitro 3T3-L1 and HepG2 cells and in vivo high-fat diet-induced obesity mice.

Abstract

This study investigated the potential lipid inhibitory and anti-obesity effects of compounds derived from Sargassum thunbergii in vitro and in vivo. We prepared a Celluclast-assisted hydrolysate from Sargassum thunbergii (STC) and three fractional ethanol precipitates (STCF1, STCF2, STCF3). We investigated their proximate composition, and anti-obesity effects in vitro and in vivo. STC and STCFs all significantly reduced intracellular lipid accumulation in PA-treated 3T3-L1 and HepG2 cells. STC, STCF1, and STCF3 had profound anti-obesity effects on high fat diet (HFD)-fed obesity model mice. Oral administration of STC, STCF1, and STCF3 significantly reduced body weight and white adipose tissue (WAT) mass. Furthermore, serum lipid levels were significantly decreased. Additionally, adipose specific hormone levels (adiponectin and fibroblast growth factor-21 (FGF-21)) were significantly decreased, and serum insulin levels were also decreased by STC, STCF1, and STCF3 treatment. A mechanistic study revealed that the adipogenesis and lipolysis associated proteins in epididymal adipose tissue, and free fatty acid oxidation in liver tissues were effectively regulated by STC, STCF1, and STCF3. Overall, our findings show the potent anti-obesity effects of STC, STCF1, and STCF3, achieved by regulation of adipogenesis, lipolysis, and the fatty acid oxidation pathway in HFD-treated obesity model mice.